Attenuated Salmonella typhimurium containing interleukin-2 decreases MC-38 hepatic metastases: A novel anti-tumor agent

Cancer Biotherapy and Radiopharmaceuticals

Volumn 11, Issue 2, 1996, Pages 145-153

  Saltzman, Daniel A ^a   Heise, Charles P ^b   Hasz, Diane E ^b   Zebede, Marcela ^b   Kelly, Sandra M ^d   Curtiss III, Roy ^e   Leonard, Arnold S ^a   Anderson, Peter M ^c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c MAYO CLINIC   (United States)

^d Megan Health Inc   (United States)

^e WASHINGTON UNIVERSITY   (United States)

Author keywords

Attenuated salmonella typhimurium; Interleukin 2; Metastases

Indexed keywords

INTERLEUKIN 2;

ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CYTOTOXICITY TEST; ELECTROPORATION; EXPRESSION VECTOR; HUMAN; LIVER METASTASIS; MICROBIAL ATTENUATION; NONHUMAN; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM;

ANIMALS; FEMALE; INTERLEUKIN-2; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C57BL; SALMONELLA TYPHIMURIUM; SPLEEN;

EID: 0029936191     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1996.11.145     Document Type: Article

References (26)

1. Smith KA. Lowest Dose Interleukin-2 Immunotherapy. Blood 1993;81(6): 1414.
2. Kintzel PE and Calis KA. Recombinant Interleukin-2 : A Biological Response Modifier. Clinical Pharmacy 1991;10:110.
3. Anderson PM and Sorenson MA. Interleukin-2 Effects of Route and Formulation on Clinical Phannokinetics. Clinical Pharmacokinetics 1994;27(1):19.
4. Whittington R and Faulds D. Interleukin-2: A Review of its Pharmacologic Properties and Therapeutic Use in Patients with Cancer Drugs 1993;46(3):446.
5. Marincola F. Interleukin 2. Biologic Therapy of Cancer Updates 1994,4(3):1.
6. Rosenberg SA. The Development of New Immunotherapies for the Treatment of Cancer using Interleukin-2. Ann Surg 1988; 208:121.
7. Grimm EA and Owen-Schaub L. The IL-2 Mediated Amplification of Cellular Cytoxicity. J Cell Bioch 1991;45:335.
8. Loeffler CM, Platt JL, Anderson PM, Katsanis E, et al. Anti tumor Effects of Interleukin-2 Liposomes and Anti-CD3 Stimulated T-Cells against MCA-38 Hepatic Metastases. Cancer Research 1991;51:2127.
9. Anderson PM, Katsanis E, Leonard AS, Schow D, Loeffler CM, Goldstein MB, and Ochoa AC. Increased Local Anti tumor Effects on Interleukin-2 Liposomes in Mice with MC A-106 Sarcoma Pulmonary Metastases. Cancer Res 1990;50:1853.
10. Anderson PM, Katsanis E, Sencer SF, Hasz D, Ochoa AC, and Bostrom B. Depot Characteristics and Biodistribution of IL-2 Liposomes: Importance of Route. J Immmunother 1993;12.19.
11. Anderson PM, Hasz D, Dickerell L, Sencer S. Interleukin-2 in Liposomes: Increased Intravenous Potency and Less Pulmonary Toxicity in the Rat Drug Devel Res 1992;27:15.
12. Anderson PM, Hanson DH, Hasz D, Halet MR, Blazar BR, and Ochoa AC Cytokines in liposomes: Depot Preparations of IL-1, IL-2, IL-6, GM-CSF, and Gamma Interferon. Cytokine 1994;6:92.
13. Curtiss III R and Kelly SM. Salmonella typhimuriun Deletion Mutants Lacking Adenylate Cyclase and Cyclic AMP Receptor Protein Are Avirulent and Immunogenic. Infection and Immunity 1987;55(12):3035.
14. Gulig PA and Curtiss III R. Plasmid-Associated Virulence of Salmonella typhimurium. Infection and Immunity 1987;55(12):2891.
15. + Expression-Cloning Vector: Stable Maintenance and High Level Expression of Cloned Genes in a Salmonella Vaccine Strain. Biotechnology 1988;6:693.
16. Molecular Cloning: A Laboratory Manual. Second Edition. Sambrook J, Fritsch EF, and Maniatis T. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York. 1989.
17. Katsanis E, Anderson PM, Filopovich AH, Hasz DE, Rich ML, Loeffler CM, Ochoa AC, Weisdorf DJ. Proliferation and Cytolytic function of anti-CD3+ Interleukin-2 Stimulated Peripheral Blood Mononuclear Cells Following Bone Marrow Transplant. Blood 1991;78:1286.
18. Lafreniere R and Rosenberg SA. A Novel Approach to the Generation and Identification of Hepatic Metastases in a Murine Model. JNCI 1986;76(2):309.
19. Dunlap NE, Benjamin WH Jr, McCall RDJr, Tilden AB, and Briles DE. A 'Safe-site' for Salmonella typhimurium is within Splenic Cells During the Early Phase of Infection in Mice. Microbial Pathogenesis 1991;10:297
20. Schmidt C, Verschueren H, Toussaint-Demylle D, van den Berg T, Kraal G, and DeBaestselier P. The Role of the Spleen in the Organ-Specific Metastases of Murine BW 5147 T Lymphomas. Clin Exp Metastases 1994;12:164.
21. Schodel F, Kelly SM, Peterson DL, Milich DR, and Curtiss III R. Hybrid Hepatitis B Virus Core-Pre-S Proteins Synthesized in Avirulent Salmonella typhimurium and Salmonella typhi for Oral Vaccination. Infect Immun 1994;62(5):1669.
22. Dusek DM, Progulske-Fox A, and Brown TA. Systemic and Mucosal Immune Responses in Mice Orally Immunized with Avirulent Salmonella typhimurium Expressing a Cloned Porphyromonas gingivalis Hemagglutinin. Infect Immun 1994;62(5):1652.
23. Redman TK, Harmon CC, and Michalek SM. Oral Immunization with Recombinant Salmonella tyhimurium Expressing Surface Protein Antigen A of Streptococcus sobrinus: Persistence and Induction of Humoral Responses in Rats. Infect Immun 1994;62(8):3162.
24. Tacket CO, Hone DM, Curtiss m R, Kelly SM, Losonsky G, Guers L, Harris AM, Edelman R, and Levine MM. Comparison of the Safety and Immunogenicity of △aroC △aroD and △cya △crp Salmonella typhi Strains in Adult Volunteers Infection and Immunity 1992;60(2):536.
25. Parker SL, Tong T, Bolden S, and Wingo PA. Cancer Statistics 1996; CA.,46(1):5.
26. Blumgart LH and Fong Y. Surgical Options in the Treatment of Hepatic Metastases from Colorectal Cancer. Current Problems in Surgery 1995;32(5):333